- cafead May 01, 2023 at 10:12: AM
via Longer-acting formulas have made the treatment of schizophrenia more convenient and reliable for patients. Now, stepping to the plate with another long-acting treatment are Otsuka and Lundbeck.
On Thursday, the FDA signed off on Abilify Asimtufii, an extended-release, injectable suspension administered every two months. The drug is for treating adults with schizophrenia and for maintenance in adults with bipolar I disorder.
article source
On Thursday, the FDA signed off on Abilify Asimtufii, an extended-release, injectable suspension administered every two months. The drug is for treating adults with schizophrenia and for maintenance in adults with bipolar I disorder.
article source